Your browser doesn't support javascript.
loading
Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification.
Notter, Markus; Thomsen, Andreas R; Nitsche, Mirko; Hermann, Robert M; Wolff, Hendrik A; Habl, Gregor; Münch, Karin; Grosu, Anca-L; Vaupel, Peter.
Afiliación
  • Notter M; Department of Radiation Oncology, Lindenhofspital Bern, 3012 Bern, Switzerland.
  • Thomsen AR; Department of Radiation Oncology, Medical Center, University of Freiburg, 79106 Freiburg, Germany.
  • Nitsche M; German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Hermann RM; Center for Radiotherapy and Radiooncology Bremen and Westerstede, 28239 Bremen, Germany.
  • Wolff HA; Center for Radiotherapy and Radiooncology Bremen and Westerstede, 28239 Bremen, Germany.
  • Habl G; Department of Radiology, Nuclear Medicine and Radiotherapy, Radiology Munich, 80333 Munich, Germany.
  • Münch K; Department of Radiation Oncology, Medical Center, University of Regensburg, 93053 Regensburg, Germany.
  • Grosu AL; Department of Radiology, Nuclear Medicine and Radiotherapy, Radiology Munich, 80333 Munich, Germany.
  • Vaupel P; Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Cancers (Basel) ; 12(3)2020 Mar 06.
Article en En | MEDLINE | ID: mdl-32155740
Effective tumor control in patients suffering from unresectable locally recurrent breast cancer (LRBC) in pre-irradiated areas can be achieved by re-irradiation combined with superficial hyperthermia. Using this combined modality, total re-irradiation dose and toxicity can be significantly reduced compared to conventionally fractionated treatment schedules with total doses of 60-66 Gy. Applying contact-free, thermography-controlled water-filtered infrared-A superficial hyperthermia, immediately followed by hypofractionated re-irradiation, consisting of 4 Gy once per week up to a total dose of 20 Gy, resulted in high overall response rates even in large-sized tumors. Comparability of clinical data between different combined Hyperthermia (HT)/Radiotherapy (RT) treatment schedules is impeded by the highly individual characteristics of this disease. Tumor size, ranging from microscopic disease and small lesions to large-sized cancer en cuirasse, is described as one of the most important prognostic factors. However, in clinical studies and analyses of LRBC, tumor size has so far been reported in a very heterogeneous way. Therefore, we suggest a novel, simple and feasible size classification (rClasses 0-IV). Applying this classification for the evaluation of 201 patients with pre-irradiated LRBC allowed for a stratification into distinct prognostic groups.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza